Idhifa
Drug
Celgene Corporation
Total Payments
$14.8M
Transactions
1,029
Doctors
486
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $246,382 | 7 | 0 |
| 2023 | $559,580 | 10 | 0 |
| 2022 | $402,274 | 13 | 0 |
| 2021 | $643,175 | 16 | 5 |
| 2020 | $513,359 | 88 | 71 |
| 2019 | $2.1M | 129 | 50 |
| 2018 | $4.1M | 359 | 207 |
| 2017 | $6.2M | 407 | 231 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.6M | 357 | 98.3% |
| Consulting Fee | $131,695 | 23 | 0.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,575 | 15 | 0.3% |
| Travel and Lodging | $27,832 | 57 | 0.2% |
| Education | $21,360 | 24 | 0.1% |
| Food and Beverage | $13,638 | 549 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,645 | 4 | 0.0% |
Payments by Type
Research
$14.6M
357 transactions
General
$251,746
672 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AG-221-C-001 | Celgene Corporation | $3.9M | 16 |
| AG-221-C-001 - A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hemat | Celgene Corporation | $1.4M | 15 |
| AG-221-AML-005 - Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) | Celgene Corporation | $1.3M | 10 |
| AG-221-AML-004 | Celgene Corporation | $1.1M | 14 |
| AG-221-AML-005 | Celgene Corporation | $815,026 | 8 |
| Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) (AG-221-AML-005) | Celgene Corporation | $758,567 | 0 |
| A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation (AG-221-C-001) | Celgene Corporation | $715,449 | 12 |
| AG-221-AML-004 - A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia H | Celgene Corporation | $625,533 | 4 |
| A Phase 1 Open-Label Single-Dose Study to Assess t | Celgene Corporation | $558,256 | 0 |
| AG221-CL-MDS-PI-008601 - Targeted therapy with the IDH2-inhibitor enasidenib (AG221) for high-risk IDH2-mutant MDS | Celgene Corporation | $462,222 | 0 |
| BAML-16-001-S3 | Celgene Corporation | $389,925 | 0 |
| Targeted therapy with the IDH2-inhibitor enasidenib (AG221) for high-risk IDH2-mutant MDS | Celgene Corporation | $318,636 | 0 |
| A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (AG-221-AML-004) | Celgene Corporation | $257,412 | 3 |
| A Pilot Study of Enasidenib for Patients with Clonal Cytopenia of Undetermined Significance and Mutations in IDH2 | Celgene Corporation | $244,053 | 0 |
| Targeted therapy with the IDH2-inhibitor enasidenib (AG221) for high-risk IDH2-mutant MDS (AG221-CL-MDS-PI-008601) | Celgene Corporation | $232,469 | 0 |
| A Phase 1 Open-Label Single-Dose Study to Assess t - A Phase 1 Open-Label Single-Dose Study to Assess the Pharmacokinetics of Enasidenib (CC 90007) in Subjects with Mild, Moderate and Severe Hepatic Impairment | Celgene Corporation | $206,115 | 0 |
| An Open-Label Study to Assess the Safety and Pharmacokinetics of Enasidenib (AG-221, CC-90007) in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) with an Isocitrate Dehydrogenase-2 (IDH2) Mutation | Celgene Corporation | $203,819 | 0 |
| Pilot Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients with IDH2 Mutation | Celgene Corporation | $182,272 | 0 |
| An open label, single arm, investigator-initiated trial to evaluate the ability of enasidenib to decrease red blood cell transfusion-dependence in patients with IDH2 wild-type myeloid malignancies | Celgene Corporation | $158,508 | 0 |
| AG221-CL-AML-PI-12839 - A Phase I study of IDH2 inhibition using enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms following allogeneic stem cell transplantation | Celgene Corporation | $156,267 | 0 |
Top Doctors Receiving Payments for Idhifa — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Miami, FL | $37.82 | 1 |
| , MD | Gastroenterology | Philadelphia, PA | $37.01 | 2 |
| , MD | Hematology | Chicago, IL | $36.47 | 3 |
| , MD | Specialist | Spokane, WA | $36.00 | 2 |
| , MD | Radiation Oncology | Cleveland, OH | $35.59 | 2 |
| , MD | Hematology & Oncology | Canfield, OH | $35.39 | 2 |
| , MD | Hematology & Oncology | Little Rock, AR | $34.37 | 2 |
| Daniel Lee | Medical Oncology | New York, NY | $34.06 | 1 |
| , M.D | Hematology & Oncology | New York, NY | $33.99 | 1 |
| , MD | Radiation Oncology | Drexel Hill, PA | $33.04 | 2 |
| , M.D | Medical Oncology | Memphis, TN | $32.56 | 1 |
| , MD | Hematology & Oncology | Fort Wayne, IN | $32.29 | 3 |
| , M.D | Hematology & Oncology | Houston, TX | $31.99 | 1 |
| , M.D, PH.D | Clinical Pathology/Laboratory Medicine | New York, NY | $31.99 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Fort Wayne, IN | $31.37 | 2 |
| , MD | Specialist | Little Rock, AR | $31.31 | 2 |
| , M.D | Hematology & Oncology | Tupelo, MS | $30.30 | 2 |
| , MD PHD | Hematology & Oncology | Golden, CO | $30.23 | 1 |
| , MD | Specialist | Delta, CO | $29.22 | 2 |
| , M.D | Hematology & Oncology | Roswell, NM | $28.98 | 2 |
| , MD | Hematology | Cincinnati, OH | $28.50 | 2 |
| , M.D | Hematology & Oncology | Torrance, CA | $28.49 | 1 |
| Jun Gong | Student in an Organized Health Care Education/Training Program | West Hollywood, CA | $28.49 | 1 |
| , M.D | Pediatrics | Torrance, CA | $28.49 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Torrance, CA | $28.49 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $14.8M
- E.R. Squibb & Sons, L.L.C. $28,163
Product Information
- Type Drug
- Total Payments $14.8M
- Total Doctors 486
- Transactions 1,029
About Idhifa
Idhifa is a drug associated with $14.8M in payments to 486 healthcare providers, recorded across 1,029 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2024. In 2024, $246,382 was paid across 7 transactions to 0 doctors.
The most common payment nature for Idhifa is "Unspecified" ($14.6M, 98.3% of total).
Idhifa is associated with 20 research studies, including "AG-221-C-001" ($3.9M).